New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2012
10:00 EDTLNCO, Z, RDS.A, AAPL, SRPT, SMBL, BP, ATRS, RLGY, SNDK, DNKNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Apple (AAPL) initiated with a Buy at Citigroup... BP (BP) initiated with an Outperform at Exane BNP Paribas... Dunkin' Brands (DNKN) initiated with a Buy at UBS... Royal Dutch Shell (RDS.A) initiated with an Underperform at Exane BNP Paribas... SanDisk (SNDK) initiated with an Outperform at Credit Suisse... Silicon Laboratories (SLAB) initiated with an Outperform at Pacific Crest... Smart Balance (SMBL) initiated with a Top Pick at RBC Capital... Zillow (Z) initiated with an Equal Weight at Morgan Stanley... Sarepta (SRPT) initiated with an Outperform at Burrill... Realogy (RLGY) initiated with a Buy at CRT Capital... LinnCo (LNCO) initiated with a Strong Buy at Raymond James... Antares Pharma (ATRS) initiated with a Buy at Guggenheim.
News For A;SNDK;SMBL;Z;RLGY;SRPT;LNCO;ATRS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
November 20, 2015
09:48 EDTSRPTSarepta rallies sharply, levels to watch
Subscribe for More Information
09:19 EDTSRPTSarepta competitive advantage being read into Biomarin docs, says Piper Jaffray
Subscribe for More Information
08:05 EDTSRPTBioMarin drops after FDA posts review of DMD drug drisapersen
Shares of BioMarin are down 7% to $96.01 after the FDA posted a review of the company's Duchenne muscular dystrophy treatment drisapersen ahead of Tuesday's panel vote. Sarepta Therapeutics (SRPT), which is developing its own treatment for DMD, is trading higher while PTC Therapeutics (PTCT) is moving lower. Reference Link
November 19, 2015
16:10 EDTAAgilent increases cash dividend to 11.5c per share
Subscribe for More Information
14:49 EDTSRPTBefore the Move: Watch BioMarin into FDA advisory committee
BioMarin Pharmaceutical (BMRN), which develops and commercializes pharmaceuticals for serious diseases and medical conditions including Duchenne muscular dystrophy, or DMD, is awaiting an FDA advisory committee for its DMD drug drisapersen, which is brand named Kyndrisa. WHAT'S NEW: The Peripheral and Central Nervous System Drugs Advisory Committee is meeting on Tuesday, November 24 to discuss the New Drug Application, or NDA, for Biomarin's drisapersen. It is expected that briefing documents related to that meeting will be posted on the FDA's website tomorrow, Friday, November 20. BULLISH TAKE: On November 15, Leerink analyst Joseph Schwartz said he believes the FDA will feel compelled to approve at least one DMD drug due to "public attention and vocal demand," and says that most likely both drisapersen and Sarepta Therapeutics' (SRPT) eteplirsen will be approved. However, he also makes a case where eteplirsen is not approved due to the "extremely limited" clinical data on the drug. Schwartz noted that drisapersen's advisory panel on November 24 happens first and will be important for both companies, adding that he sees "significant" upside potential for BioMarin. On November 18, Goldman Sachs said it views the risk/reward in BioMarin as favorable, with the advisory committee as a key catalyst on the company's path to non-GAAP profitability. Goldman has a Buy rating on BioMarin shares. On November 19, Jefferies analyst Gena Wang wrote that a buy-side survey the firm conducted suggests positive expectations for BioMarin's advisory committee. Wang, who said the survey of 58 investors suggests buy-side expectations of a positive panel for Kyndrisa are 62%, noted that a positive outcome could push BioMarin higher by almost 20%, and positively impact peers PTC Therapeutics (PTCT) and Sarepta by over 20% and 6%, respectively. BAIRD CAUTIOUS: On November 19, Baird analyst Brian Skorney wrote a note titled "A Skeptic's Guide to DMD Regulatory Reviews" where he says the firm has "increasingly come to believe that the FDA is more likely to reject the NDA's for drisapersen and eteplirsen," although he notes the risk reward for BioMarin is skewed to the upside -- with 20% upside potential on approval, but only 10% downside potential on rejection. Baird has a Neutral rating on BioMarin. Skorney sees a 30% probability both drugs get approved during this review period, a 5% chance BioMarin's drug gets approved and Sarepta's gets rejected, a 5% chance Sarepta's gets approved and BioMarin's gets rejected, and a 60% chance that both get rejected. PRICE ACTION: In afternoon trading on Thursday, shares of BioMarin were down about 4.5% to $102.88, while shares of peers Sarepta and PTC Therapeutics were down 8% and 9.5%, respectively.
08:28 EDTSRPTBaird sees 60% chance BioMarin, Sarepta DMD drugs both get rejected
Baird analyst Brian Skorney said he increasingly thinks that the FDA is more likely to reject the NDA's for the two Duchenne muscular dystrophy drugs it will soon review, BioMarin's (BMRN) drisapersen and Sarepta's (SRPT) eteplirsen, though he notes that his confidence in any of the various approval/rejection scenarios is low. Skorney sees a 30% probability both drugs get approved during this review period, a 5% chance BioMarin's drug gets approved and Sarepta's gets rejected, a 5% chance Sarepta's gets approved and BioMarin's gets rejected, and a 60% chance that both get rejected. Skorney, who sees 20% upside potential and 10% downside potential for Biomarin based on this event, keeps a Neutral rating on its shares. The analyst thinks the risk-reward for Sarepta, however, is "massively" skewed to the upside, with 250% upside potential compared to 50% downside, and keeps an Outperform rating on its shares.
07:23 EDTSRPTBuy-side sees 62% chance of positive BioMarin panel, says Jefferies
Jefferies analyst Gena Wang says her firm's survey of 58 investors suggests buy-side expectations of a positive FDA panel on November 24 for BioMarin's (BMRN) Kyndrisa are 62%. Both positive and negative outcomes are expected to result in significant moves for all three stocks developing treatments for Duchenne muscular dystrophy, or BioMarin, Sarepta (SRPT) and PTC Therapeutics (PTCT), Wang tells investors in a research note. Investors expect a positive Kyndrisa outcome to push BioMarin shares 19% higher, PTC shares 23% higher and Sarepta shares 6% higher, the analyst points out. She notes that a negative panel vote is expected to drive all three stocks 20%-30% lower.
November 18, 2015
10:29 EDTSNDKOptions with increasing implied volatility
Options with increasing implied volatility: TERP CSC SGMS RH BBRY ULTA SNDK ORCL NKE VNET
08:19 EDTSNDKRBC Capital to hold a tour
Subscribe for More Information
November 17, 2015
08:44 EDTSRPTSarepta says eteplirsen study shows 'positive' results
Subscribe for More Information
08:43 EDTAAgilent pullback after earnings a buying opportunity, says Cowen
Cowen said any pullback in Agilent after its Q4 earnings report would be a buying opportunity. Even though guidance was lower than expected, the firm still thinks 2017 targets are achievable. Cowen maintained its Market Perform rating and $39 price target on Agilent shares.
November 16, 2015
18:26 EDTAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Nuance (NUAN), up 9.5%. ALSO HIGHER: Ocera Therapeutics (OCRX), up 26.6% after announcing Phase 1 study results for the company's oral formulation of OCR-002. DOWN AFTER EARNINGS: Urban Outfitters (URBN), down 11.5%... Agilent (A), down 1.3%. ALSO LOWER: Wayfair (W), down 2% after Bloomberg reported that Whitney Tilson said that Wayfair is currently his largest short.
16:10 EDTAAgilent reports Q4 LSAG revenue down 4% to $515M
Subscribe for More Information
16:09 EDTAAgilent sees FY16 adjusted EPS $1.85-$1.91, consensus $1.97
Sees FY16 revenue $4.15B-$4.17B, consensus $4.21B.
16:08 EDTAAgilent sees Q1 adjusted EPS 42c-44c, consensus 47c
Subscribe for More Information
16:07 EDTAAgilent reports Q4 adjusted EPS 50c, consensus 47c
Subscribe for More Information
15:02 EDTANotable companies reporting after market close
Subscribe for More Information
10:25 EDTSNDKUBS trims Apple target, says iPhone partner cut production forecast
Hon Hai, which manufactures Apple's (AAPL) iPhones, expects to assemble significantly fewer iPhones this quarter than in the same period in 2014, UBS wrote in a note to investors today. WHAT'S NEW: Hon Hai Precision Industry, also known as Foxconn, is expected to assemble 10% fewer iPhones this quarter than in the same period in 2014, said UBS analyst Steven Milunovich, citing work from fellow UBS analyst Arthur Hsieh. Previously, companies that supply force touch components for iPhones saw a 10%-15% reduction in their orders, the analyst reported. These developments "are not encouraging," but Apple had previously ordered a large number of iPhones for Q4, according to Milunovich. Overall iPhone demand "could still be decent," he believes. However, the analyst lowered his iPhone sales estimate for Apple's March quarter to 61M from 62.5M, asserting that iPhone sales on China's November 11 Singles Day holiday may have come in below expectations. Based on October search volumes, he continues to believe that demand for iPhone units in the fourth quarter of the calendar year will be 75M, in-line with the consensus outlook. Milunovich trimmed his price target on Apple to $140 from $150 but kept a Buy rating on the shares. WHAT'S NOTABLE In a note to investors on November 10, Credit Suisse reported that it was cutting its estimates for 2016 iPhone sales. The firm expects sales of the device to fall 10.4% in the first quarter versus the same period in 2015, and it predicts that iPhone sales will decline 5.5% year-over-year in 2016. Suppliers with greater than 10% exposure to Apple include Avago (AVGO), SanDisk (SNDK), Analog Devices (ADI), Broadcom (BRCM), Texas Instruments (TXN), NXP Semiconductors (NXPI) and Fairchild (FCS), Credit Suisse reported. The firm said it continues to have a negative view of the smartphone sector. PRICE ACTION: In early trading, Apple added nearly 1% to $113.34.
07:39 EDTSNDKNetlist says appeals court upholds validity of LRDIMM patent against Inphi
Subscribe for More Information
07:16 EDTSRPTFDA likely feels compelled to approve at least one DMD drug, says Leerink
Leerink analyst Joseph Schwartz says the FDA likely feels compelled to approve at least one of the exon skipping drugs to treat Duchenne muscular dystrophy in this review cycle. There is so much public attention and vocal demand in the DMD community, Schwartz tells investors in a research note. The FDA advisory panel on BioMarin's (BMRN) drisapersen is on November 24 while the panel on Sarepta's (SRPT) eteplirsen is tentatively scheduled for January 22, 2016. The greatest likelihood is that both drugs are approved, Schwartz contends. Shares of BioMarin have "significant" upside potential on a positive panel vote as many investors still doubt that drisapersen is approvable based on existing data, and approval would "greatly aid" the company's goal to reach profitability, the analyst argues. He reiterates an Outperform rating on BioMarin and a Market Perform rating on Sarepta. Jefferies analyst Eun Yang said on Friday that regulatory experts she spoke with see a high likelihood of a positive FDA panel vote BioMarin.
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use